PUMA BIOTECHNOLOGY INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
PBYI$8.14-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2023 and 2022
(in thousands, except share and per share data)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $84,585 | $76,201 |
| Marketable securities | 11,354 | 4,873 |
| Accounts receivable, net of allowance for credit loss of $881 and $0 | 47,837 | 40,350 |
| Inventory, net | 7,080 | 4,526 |
| Prepaid expenses, current | 4,417 | 5,902 |
| Other assets, current | 912 | 2,429 |
| Total current assets | 156,185 | 134,281 |
| Lease right-of-use assets, net | 7,792 | 11,362 |
| Property and equipment, net | 855 | 1,146 |
| Intangible assets, net | 60,871 | 70,610 |
| Restricted cash, long-term | 2,091 | 2,591 |
| Prepaid expenses and other, long-term | 2,734 | 2,069 |
| Total assets | $230,528 | $222,059 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,889 | $6,440 |
| Accrued expenses, current | 52,721 | 53,034 |
| Accrued in-licensed rights, current | — | 12,500 |
| Post-marketing commitment liability, current | 975 | 1,370 |
| Lease liabilities, current | 4,800 | 4,140 |
| Current portion of long-term debt | 33,997 | — |
| Total current liabilities | 99,382 | 77,484 |
| Accrued expenses, long-term | 121 | 7,391 |
| Lease liabilities, long-term | 7,034 | 11,834 |
| Post-marketing commitment liability, long-term | 4,890 | 5,435 |
| Long-term debt, net | 65,659 | 98,307 |
| Total liabilities | 177,086 | 200,451 |
| Commitments and contingencies (Note 13) | ||
| Stockholders' equity: | ||
| Common stock - $.0001 par value per share; 100,000,000 shares authorized; 47,646,787 shares issued and outstanding at December 31, 2023 and 46,345,660 issued and outstanding at December 31, 2022 | 5 | 5 |
| Additional paid-in capital | 1,398,605 | 1,388,358 |
| Accumulated other comprehensive loss | (4) | — |
| Accumulated deficit | (1,345,164) | (1,366,755) |
| Total stockholders' equity | 53,442 | 21,608 |
| Total liabilities and stockholders' equity | $230,528 | $222,059 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.